New ketamine-type nasal spray can help 30,000 Australians suffering depression
A new nasal spray, that's chemically similar to Ketamine, is being added to the Pharmaceutical Benefits Scheme, for adults with treatment resistant depression.
Spravato® (Esketamine) is the first new type of depression medicine to be added to the PBS in 30 years.
Professor Ian Hickie AO, Co-Director of Health and Policy, Brain and Mind Centre, University of Sydney says Spravato targets a different chemical in the brain, than traditional antidepressants.
'Treatment resistant depression is a very important and a very disabling illness in Australia.
About one in seven Australians has a depressive illness, about two thirds of those will respond to commonly available psychological or medical treatments.'
'You will not be able to get this medicine from your GP and take it home and squirt it up your own nose.'
Instead, it will be provided under strict medical supervision.
Twice a week at first, weekly for the next month, and then weekly or fortnightly until depressive symptoms improve.
The treatment will only be given to patients who have not responded adequately to at least two different antidepressants of adequate dose and duration.
Pensioner or concession card holders will pay just $7.70 and general patients will pay $31.60 for each dose of the medicine.
Veteran Garth Camac has been living with treatment resistant depression for 15 years, and untreated depression for 15 before that.
'It is an expensive medication and having it added to the PBS is a great thing.'
During his service in the Australian Army, he was deployed to Iraq twice.
In Malaysia, completing training, five of his men died in a horrific car accident.
Life after war was a battle he couldn't seem to win.
'I've been in a really uncomfortable place where I've had to decide whether or not today is the day to kill myself, or can I go a little bit further.'
'I had no plans to be alive at 50.'
He's now 52.
For the past two years, he's been taking Spravato.
'It's taken me two years to get to where I am now.'
'I enjoy being out in public now, I'm not scanning for danger, I'm not worrying that something will explode.'
If you or someone you know is struggling:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
18 hours ago
- Sydney Morning Herald
Forget 10,000 steps. The Japanese walking method is easier and faster
As fitness trends go, there's lots to like about Japanese walking. It's free, easy, time efficient and suits anyone unused to exercise. While walking 10,000 steps can take up to 100 minutes, the Japanese walking method takes just half an hour at a time – and the payoff could be healthier blood pressure, better cardio fitness and (maybe) better lower-body strength. Also called interval walking, it was developed by Japanese researchers two decades ago as a way of turning walking into a workout, and is like a soft version of High Intensity Interval Training. With HIIT, you switch between bursts of high intensity movements, like sprinting, and a few minutes of slower paced exercise that let you recover. With interval walking you're alternating three minutes of walking at a slower pace with three minutes of brisk walking at 70 per cent of your maximum heart rate. 'If you're very unfit this could be a great way to kick-start a journey to better fitness. To someone whose fitness level is low, brisk walking is a high intensity activity,' says Dr Angelo Sabag, lecturer in exercise physiology at the University of Sydney. There are good reasons to make a walk more intense. 'Exercising at higher intensities helps your heart pump blood more efficiently and improves how your body delivers and uses oxygen. Over time this makes everyday tasks, like walking up a hill feel easier because your body can meet the energy demands more effectively.' Although the Japanese research originally focused more on heart health, other studies have since found that, compared with walking at a steady pace, it can improve blood glucose control for people with diabetes – at least in the short term. Loading 'Most studies have only followed people for a few months, so it's hard to say how effective interval walking is for long-term glucose control. It could be helpful if done regularly, but to continue seeing improvements over time, you'll likely need to gradually increase the intensity and/or duration of exercise,' Sabag says. Another limitation of interval walking could be its effect on leg strength – the original Japanese research suggested that it may help maintain strength in the thigh muscles.
The Age
18 hours ago
- The Age
Forget 10,000 steps. The Japanese walking method is easier and faster
As fitness trends go, there's lots to like about Japanese walking. It's free, easy, time efficient and suits anyone unused to exercise. While walking 10,000 steps can take up to 100 minutes, the Japanese walking method takes just half an hour at a time – and the payoff could be healthier blood pressure, better cardio fitness and (maybe) better lower-body strength. Also called interval walking, it was developed by Japanese researchers two decades ago as a way of turning walking into a workout, and is like a soft version of High Intensity Interval Training. With HIIT, you switch between bursts of high intensity movements, like sprinting, and a few minutes of slower paced exercise that let you recover. With interval walking you're alternating three minutes of walking at a slower pace with three minutes of brisk walking at 70 per cent of your maximum heart rate. 'If you're very unfit this could be a great way to kick-start a journey to better fitness. To someone whose fitness level is low, brisk walking is a high intensity activity,' says Dr Angelo Sabag, lecturer in exercise physiology at the University of Sydney. There are good reasons to make a walk more intense. 'Exercising at higher intensities helps your heart pump blood more efficiently and improves how your body delivers and uses oxygen. Over time this makes everyday tasks, like walking up a hill feel easier because your body can meet the energy demands more effectively.' Although the Japanese research originally focused more on heart health, other studies have since found that, compared with walking at a steady pace, it can improve blood glucose control for people with diabetes – at least in the short term. Loading 'Most studies have only followed people for a few months, so it's hard to say how effective interval walking is for long-term glucose control. It could be helpful if done regularly, but to continue seeing improvements over time, you'll likely need to gradually increase the intensity and/or duration of exercise,' Sabag says. Another limitation of interval walking could be its effect on leg strength – the original Japanese research suggested that it may help maintain strength in the thigh muscles.
9 News
3 days ago
- 9 News
First medicine for sleep apnoea approved for use by the TGA
Your web browser is no longer supported. To improve your experience update it here The Therapeutic Goods Administration has approved the first medicine to treat sleep apnoea. Mounjaro, which has the active ingredient tirzepatide, is widely used to treat type 2 diabetes. However, the TGA has today expanded the drug's usage to include obstructive sleep apnoea for adults living with obesity. A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity. (iStock) This makes Mounjaro the first and only medicine for obstructive sleep apnoea in Australia. The drug has not been listed on the Pharmaceutical Benefits Scheme and will only be available through private prescription. Mounjaro can now be used to treat moderate-to-severe obstructive sleep apnoea in adults living with a body mass index (BMI) of 30 or more. Mounjaro has been approved to treat sleep apnoea in adults living with obesity. (CNN) Mounjaro cannot be used to treat type 1 diabetes, or by children and teenagers under 18 years old. Side effects associated with Mounjaro can include an upset stomach, injection site-related side effects, and low blood sugar. Obstructive sleep apnoea is the most common of all sleeping disorders and is thought to affect around 780,000 Australian adults. It occurs when a person's upper airway becomes blocked, causing breathing to be repeatedly interrupted during sleep. Professor Brendon Yee is a respiratory and sleep physician at the Woolcock Institute of Medical Research who was involved in a clinical trial of Mounjaro for obstructive sleep apnoea. Yee said the TGA decision was a "long-awaited development" in the field of sleep medicine. "For the first time, people with weight-related obstructive sleep apnoea can be treated with a medicine that addresses the underlying cause of their condition," Yee said. "This marks a significant milestone in the treatment of this debilitating sleep disorder. "Obstructive sleep apnoea can affect anyone, and obesity is the single greatest cause of the condition. "At least 70 per cent of people living with obstructive sleep apnoea also live with obesity." health national medical medicine Sleep obesity CONTACT US
